08 Sep Exercise of Warrants
Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR).
Galileo Resources Plc
(“Galileo” or “the Company”)
Exercise of Warrants
Galileo Resources plc (“Galileo “or the “Company”) confirms that it has issued a total of 1,250,000 fully paid ordinary shares in the Company (the “New Ordinary Shares”) at a price of 0.6p per share pursuant to the exercise of warrants in terms of the Placing Agreement dated 17 October 2019 (RNS announced 18 October 2019). Application will be made for admission of the New Ordinary Shares to trading on AIM (“Admission”), with Admission expected to occur on around 14 September 2020.
Following the issue of the New Ordinary Shares, which rank pari passu to the existing ordinary shares in the Company, the Company has 768,526,193 ordinary shares in issue, all of which have voting rights. Shareholders in the Company may use this figure as the denominator for the calculation, by which they would determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority’s Disclosure and Transparency Rules.
You can also follow Galileo on Twitter: @GalileoResource
For further information, please contact: Galileo Resources PLC
|Colin Bird, Chairman
Edward Slowey, Executive Director
|Tel +44 (0) 20 7581 4477
Tel +353 (1) 601 4466
|Beaumont Cornish Limited – Nomad
Roland Cornish/James Biddle
|Tel +44 (0) 20 7628 3396|
|Novum Securities Limited – Joint Broker
Colin Rowbury /Jon Belliss
|+44 (0) 20 7399 9400|
|Shard Capital Partners LLP – Joint Broker
|Tel +44 (0) 20 7186 9952|
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact email@example.com or visit www.rns.com.